A0A0D1CZ63 AF NFT

Multidrug resistance protein fer6

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeidlo62nbrxll7yugehtmbuwhrioetkwwikyw4v27vlz5cidlzwl7y/metadata.json
IPFS of structure file: 
bafybeigifuufc3lxkczluzkbkdkgl7ugp5fymg6adp7vzwtzi55fi2vhdq/AF-A0A0D1CZ63-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x9E72a6c28d20b2443a44F1c57457a027ddE4fa17
First NFT owner address (bech32): 
genesis1nee2ds5dyzeygwjy78zhg4aqylw7f7sh87h2qv
Current NFT ID #129234 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
129234
Accession (UniProt):
A0A0D1CZ63
Name::
Multidrug resistance protein fer6
Experimental Method:
Predicted structure
Sequence source:
USTILAGO MAYDIS (STRAIN 521 / FGSC 9021)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT A0A0D1CZ63 research and analysis (ICN3D with VR)

FASTA sequences

>sp|A0A0D1CZ63|FER6_USTMA Multidrug resistance protein fer6 OS=Ustilago maydis (strain 521 / FGSC 9021) OX=237631 GN=fer6 PE=2 SV=1 MTPEASANWFSLCWFAWIDPILTAGYTRPMEKDDLYLLQPHRCSEHLGSQLLAALEKRRKQRQDYVEANPNKTDKPAKIPPLMWAMNDIVFRYFWIGGLLKLLADVGTITSPLLVRALINFGRDSYNLRGDRDQAPNLGSGVGLAIGLFLVQALCVFLNVHAFNRGFGTGIILRGALIQAIFQRGMNLSTRARTVGGLGVSKLVTLISADATRIDYAGQFFHMAWTSAVQIIICVALLIWSLSYSALPGIAVLVLMSPIQTAITKRLFALRKKSMVWTDKRNKAVNEVVGGIRVVKQFAWEEPYSVRIAELRRKEMSFHRVRLYLRSLNLALAFATPTIATVLSFVTYALVGNELDAAILFSSLSFFTLLRTPLQFLPIAWNAIVDAKNAADRIEKVFDAEIQRDQIIRDCSATNGIQLEDASFTWETAQAADTAKPVNEKKGQDSPSNEKETPVDRASTLDSLNLTVPRGTLCAIVGGVGSGKSSLISALAGEMRQIAGKVTLSGSTAVCAQTAWIQSTTIRNNIVFGNAFDPERYRYVLEVCCLLPDLDTLADGDQTIVGEKGVSLSGGQKQRLNIARALYHNSEIVLLDDCLSALDARVGADIFANVIAGDAMAGKTRLLVTHSLNVLRSCDWIVHMEEGRITEQGTYAELVESKGRVAELLLTHTKDHFEEEKKEPSKHPIDEIQETAESILDAGSASNRNSEASESTTTTVNAESKDTSNAEGVTNKTEKKDLVAPPAQAKSKALMQDEERFSGSVSRTTYLSYLNAAPLSILLPLFLVAVLVFQGSTIMSPVWLLWWQNGHFGLQQGVYMGIYAVFGITQSLGLLSMGVIFSTFTIKSATTLHHRALQRVLHAPFSFFDTTPQGRITHRFSKDMDTLDNIIGEAMRTLIGTIVQVIGSIVLIAILTPYFLIPVAVILVLYFWIAAYYRSTARELRRIDAGLRSNMHEHFSESLHGLVTIRAFGNVDAFIAENCRRIDKQNRAYWLAQTCQRWLSVRLDFLGSLLILSVAILVVASRFDISPGETGVALSYILTAQSIFGWMIRHAAELENNMSAVERVLHYANHIEQEKPYHIPQVDDALEAREWPERGEIRFEGVEAKYGSSERNVLDKLDLHIAPGEKIAFCGRTGAGKSTLVTTLLRTLELSAGTITIDGIDIASMGLHRLRSSLSLIPQDAVIYSGTLRYNLDPLDQHEDATLHDALQRTSLTDLSLDMTITEEGGNLSAGQRSLISLARAMVRKTRIVILDEATASIDQETDVQIQEVLRNEFDGITTLTVAHRIQTILHSDRVCVLDKGVIVEIGSPAELWAKEKGAFRALCDSANIRYQDGEWK